TENEO™

Experience the Modern Era of Refractive Surgery

TENEO,™ the first excimer platform to earn FDA approval in 17 years, is more than just a new laser – it's an extension of brilliance.

Purposeful and purpose-built, TENEO redefines excimer technology. Bausch + Lomb engineers designed each feature specifically for the comfort and safety of surgeons and their patients.

With TENEO's state-of-the-art features, you can deliver outcomes you need to see to believe – all with no nomogram required.

BAUSCH + LOMB

Streamline Your Workflow

TENEO's intuitive software enables a smooth and efficient process from end to end with three easy steps:

1. Select a patient
2. Choose and confirm treatment
3. Treat

Precise Engineering

Small footprint

- 29.3 sq. ft., including the patient bed
- The smallest excimer laser available in the U.S.

Advanced eye-tracker

- Operates at 1,740Hz (more than 3x the laser's repetition rate)
- The fastest eye-tracker in the U.S.

High-speed laser

- Operates at 500Hz
- The fastest ablation time in the U.S. (1.2 seconds per diopter)*

* Based on calculation using an optical zone of 6mm and a standard myopic treatment (PROSCAN mode)

Intentional Efficiency

GUI touchscreen

- Customized views
- Access to selected patient data without flipping through screens

Innovative software

- No nomogram required

Intuitive data entry

- Automatic plus-to-minus cylinder conversion

Unlimited treatment between energy checks

- Energy check every two hours

Unparalleled Experience

Adjustable microscope

- Adaptable positioning for surgeon height and posture

Customizable treatment bed

- Swing-out design for easy access
- Can be positioned for a second treatment device**
- Accommodates different body sizes
- Adjustable head positioning

** Depending on the bed design of the second device

Quiet performance

BAUSCH+LOMB

Exceptional Outcomes

With TENEO, you'll experience outcomes you need to see to believe. Look forward to incredible results such as:

At nine months postoperative

- 97.8% of eyes showed 20/25 or better and 99.9% of eyes showed 20/40 or better
- Over half of patients achieved 20/16 or better
- 34.8% of eyes gained 1 or more lines of CDVA

Comparison of Postoperative Cumulative UDVA and Preoperative CDVA[1]



Between one and nine months postoperative

90.2% of eyes maintained MRSE within 0.50 D.

Mean MRSE by Visit[1]
(All Treated Eyes)



1. Chu, R, Waring IV, G, Outcomes of LASIK Performed Using the Updated Laser Ablation Algorithm for the Correction of Myopia and Myopic Astigmatism, presented ASCRS 2024.

Exceptional Outcomes

(continued)

Patient Quality of Life / Satisfaction

- 99% of patients reported having little to no difficulty driving at night
- LASIK performed with the TENEO yielded high (98%) patient satisfaction

No / little Difficulty Performing Daily Activities[2]



Satisfaction with Present Vision[2] (somewhat to very satisfied)



2. Stonecipher, K, Endl, E, Patient-Reported Outcomes Following Lasik, Performed Using a Novel Excimer Laser for the Correction of Myopia and Myopic Astigmatism, presented at ASCRS 2024

Exceptional Outcomes

(continued)

Contrast Sensitivity

Significant post-op improvement in contrast sensitivity

Contrast Sensitivity: Without Glare



With Glare



TENEO™

Ready to experience transformed excimer technology?

Get in touch at **bauschsurgical.com/refractive/teneo/**

Indications and Important Safety Information for Technolas Teneo 317 Model 2 System

Indications for Use. The Technolas Teneo 317 Model 2 is indicated for laser-assisted in situ keratomileusis (LASIK) in: (1) Patients for the reduction or elimination of myopic astigmatism up to -10.00 D MRSE, with sphere between -1.00 D to -10.00 D and cylinder between 0.00 and -3.00 D; (2) Patients who are 22 years of age or older; (3) Patients must have a stable refraction in the last 12 months, as documented by previous clinical recordings, i.e., the spherical and cylindrical portions of the manifest distance refraction have not progressed at a rate of more than 0.50 D per year prior to the baseline examination in the eye(s) to be treated.

WARNING. Danger of injury due to failure to observe the patient selection criteria! Failure to observe the contraindications and potential adverse effects may result in serious permanent patient injury. The usage of the laser system is limited to a specific field of applications. Observe the contraindications and potential adverse effects listed in the User Manual before selecting a patient and starting any treatment.

Contraindications. Contraindications of the Technolas Teneo 317 Model 2 include patients: (1) with any type of active connective tissue disease or autoimmune disease; (2) with signs of keratoconus, abnormal corneal topography, and degenerations of the structure of the cornea (including but not limited to pellucid marginal degeneration); (3) with significant dry eyes (severe Dry Eye Syndrome). If patients have severely dry eyes, LASIK may increase the dryness. This may or may not go away. Severe eye dryness may delay healing of the flap or interfere with the surface of the eye after surgery. It may result in poor vision after LASIK; (4) for whom the combination of their baseline corneal thickness and the planned operative parameters for the LASIK procedure would result in less than 250µ of residual corneal thickness from corneal endothelium; (5) with uncontrolled diabetes; (6) with uncontrolled glaucoma; (7) with active eye infections or active inflammation: (8) with recent herpes eye infection or problems resulting from past infections; (9) with known sensitivity to medications used for standard LASIK surgery.

Potential Risks and Side Effects: (1) Miscreated flap; (2) Subconjunctival hemorrhage or bleeding; (3) Wrinkles in flap that may require a flap lift; (4) Corneal erosion/abrasion, epithelia defect; (5) Elevated IOP; (6) Debris or foreign body under flap; (7) Epithelial ingrowth under flap; (8) Debilitating visual symptoms, especially at night; (9) Decreased or fluctuating visual acuity; (10) Decreased ability to see in low-light conditions; (11) Light sensitivity; (12) Dry Eye syndrome; (13) Inadequate treatment result; (14) Regression; (15) Corneal damage; (16) Posterior vitreous detachment or retinal detachment, floaters or vascular accidents; (17) Foreign body sensation or pain (initial postoperative days); also, potentially including chronic eye pain that is resistant to therapy referred to as neuropathic pain; (18) Infection/inflammation; (19) CTK (Central Toxic Keratopathy); (20) Medication intolerance; (21) Ptosis; (22) Cataract; (23) Ocular penetration; (24) Potential risk of psychological harm.



This is not all you need to know. Please see the User Manual for a complete list of safety information, including a full list of contraindications, warnings, precautions and risks.

Caution: Federal (U.S.) law restricts this device to sale, by or on the order of a physician.

TENEO | BAUSCH+LOMB

TEN.0004.USA.24